Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy and Gefitinib as First-line Treatment in Advanced Lung Adenocarcinoma with EGFR Mutations
NCT02148380Completed
- Start
- May 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of gefitinib in non-small cell lung cancer (NSCLC) (3 arms). Primary endpoint: Progression-Free Survival at 6 months. Started May 2014; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02148380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02148380.